Prostate Cancer Managed with Active Surveillance: Role of Anatomic MR Imaging and MR Spectroscopic Imaging

被引:101
|
作者
Fradet, Vincent [2 ]
Kurhanewicz, John [1 ]
Cowan, Janet E. [2 ]
Karl, Alexander [2 ]
Coakley, Fergus V. [2 ]
Shinohara, Katsuto [2 ]
Carroll, Peter R. [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Urol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
ENDORECTAL MR; INCREMENTAL VALUE; TUMOR; MEN; PREDICTION; ANTIGEN; LOCALIZATION; SUPPRESSION; BIOPSY; MARKER;
D O I
10.1148/radiol.10091147
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the role that magnetic resonance (MR) imaging and MR spectroscopic imaging findings obtained at the time of diagnosis play in the progression of disease in patients whose prostate cancer is being managed with active surveillance and to compare the role of these findings with the role of transrectal ultrasonography (US) findings. Materials and Methods: The institutional review board approved this HIPAA-compliant retrospective study, and informed consent was obtained from all patients whose records were to be entered into the research database. All patients who had prostate cancer managed with active surveillance and who had undergone both MR imaging and MR spectroscopic imaging of the prostate and transrectal US at time of diagnosis were identified. Two urologists blinded to the clinical outcome in these patients independently reviewed and dichotomized the MR imaging report and the MR spectroscopic imaging report as normal or suggestive of malignancy. One experienced urologist performed all US examinations that were then dichotomized similarly. Uni- and multivariate (with use of standard clinical variables) Cox models were fitted to assess time to cancer progression, defined as Gleason score upgrading, prostate-specific antigen velocity of more than 0.75 (mu g . L-1)/y, or initiation of treatment more than 6 months after diagnosis. Results: The final cohort included 114 patients with a median follow-up of 59 months. Patients with a lesion that was suggestive of cancer at MR imaging had a greater risk of the Gleason score being upgraded at subsequent biopsy (hazard ratio, 4.0; 95% confidence interval: 1.1, 14.9) than did patients without such a lesion. Neither MR spectroscopic imaging nor transrectal US could be used to predict cancer progression. Conclusion: Abnormal prostate MR imaging results suggestive of cancer may confer an increased risk of Gleason score upgrade at subsequent biopsy. Although expensive, prostate MR imaging may help in counseling potential candidates about active surveillance. (C) RSNA, 2010
引用
收藏
页码:176 / 183
页数:8
相关论文
共 50 条
  • [31] Peripheral zone prostate cancer: Accuracy of different interpretative approaches with MR and MR spectroscopic imaging
    Westphalen, Antonio C.
    Coakley, Fergus V.
    Qayyum, Aliya
    Swanson, Mark
    Simko, Jeffry P.
    Lu, Ying
    Zhao, Shoujun
    Carroll, Peter R.
    Yeh, Benjamin M.
    Kurhanewicz, John
    [J]. RADIOLOGY, 2008, 246 (01) : 177 - 184
  • [32] 3D MR spectroscopic imaging in the evaluation of prostate cancer
    Rajesh, A.
    Coakley, F. V.
    Kurhanewicz, J.
    [J]. CLINICAL RADIOLOGY, 2007, 62 (10) : 921 - 929
  • [33] Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone
    Emanuele Casciani
    Elisabetta Polettini
    Luca Bertini
    Gabriele Masselli
    Paolo Emiliozzi
    Mostafà Amini
    Vito Pansadoro
    Gian Franco Gualdi
    [J]. Abdominal Imaging, 2007, 32 : 796 - 802
  • [34] Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone
    Casciani, Emanuele
    Polettini, Elisabetta
    Bertini, Luca
    Masselli, Gabriele
    Emiliozzi, Paolo
    Amini, Mostafa
    Pansadoro, Vito
    Gualdi, Gian Franco
    [J]. ABDOMINAL IMAGING, 2007, 32 (06): : 796 - 802
  • [35] Functional MR imaging of prostate cancer
    Choi, Young Jun
    Kim, Jeong Kon
    Kim, Namkug
    Kim, Kyoung Won
    Choi, Eugene K.
    Cho, Kyoung-Sik
    [J]. RADIOGRAPHICS, 2007, 27 (01) : 63 - U8
  • [36] Molecular MR Imaging of Prostate Cancer
    Kader, Avan
    Brangsch, Julia
    Kaufmann, Jan O.
    Zhao, Jing
    Mangarova, Dilyana B.
    Moeckel, Jana
    Adams, Lisa C.
    Sack, Ingolf
    Taupitz, Matthias
    Hamm, Bernd
    Makowski, Marcus R.
    [J]. BIOMEDICINES, 2021, 9 (01) : 1 - 17
  • [37] MR Imaging of Treated Prostate Cancer
    Vargas, Hebert Alberto
    Wassberg, Cecilia
    Akin, Oguz
    Hricak, Hedvig
    [J]. RADIOLOGY, 2012, 262 (01) : 26 - 42
  • [38] Optimum MR Imaging for prostate cancer
    Villeirs, G. M.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (09) : 596 - 596
  • [39] Prostate Cancer: Can Multiparametric MR Imaging Help Identify Patients Who Are Candidates for Active Surveillance?
    Turkbey, Baris
    Mani, Haresh
    Aras, Omer
    Ho, Jennifer
    Hoang, Anthony
    Rastinehad, Ardeshir R.
    Agarwal, Harsh
    Shah, Vijay
    Bernardo, Marcelino
    Pang, Yuxi
    Daar, Dagane
    McKinney, Yolanda L.
    Linehan, W. Marston
    Kaushal, Aradhana
    Merino, Maria J.
    Wood, Bradford J.
    Pinto, Peter A.
    Choyke, Peter L.
    [J]. RADIOLOGY, 2013, 268 (01) : 144 - 152
  • [40] Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla
    Mazaheri, Yousef
    Shukla-Dave, Amita
    Goldman, Debra A.
    Moskowitz, Chaya S.
    Takeda, Toshikazu
    Reuter, Victor E.
    Akin, Oguz
    Hricak, Hedvig
    [J]. MAGNETIC RESONANCE IMAGING, 2019, 55 : 93 - 102